Sign In
Buy CVAC
$4.66
+0 (+0%)
At Close: Apr 02, 2026
7 Global Stocks That Are Worth Adding to Your Portfolio
04:45pm, Thursday, 20'th May 2021
Here's a list of seven global stocks that can be added to the portfolio for exposure to growth themes from different regions. The post 7 Global Stocks That Are Worth Adding to Your Portfolio appeared
CureVac-GSK's Second-Gen COVID-19 Vaccine Candidate Shows Encouraging Action Against Variants In Animal Study
09:20am, Thursday, 13'th May 2021
CureVac N.V. (NASDAQ: CVAC) and GlaxoSmithKline Plc (NYSE: GSK) have released positive early data from a preclinical study of its second-generation COVID-19 vaccine with signs that the candidat
What's Up WIth BioNTech Stock And CureVac Stock Today?
08:10am, Monday, 10'th May 2021
BioNTech SE - ADR (NASDAQ: BNTX) shares were trading higher by 8.27% at $198.80 in Monday's premarket session after the company announced a Chinese joint venture to make 1 billion COVID-19 vaccine do
CureVac Could Soon Join The Fight Against COVID-19
05:43am, Monday, 10'th May 2021
CVAC is close to getting its COVID-19 vaccine approved in Europe. Its mRNA technology could potentially compete with PFE and MRNA.
CureVac's Vaccine Might Protect Against the South African Variant
11:05am, Saturday, 01'st May 2021
The promising data in mice needs to translate into humans.
Best Biotech Stocks & ETFs for mRNA, Gene Editing
05:17pm, Thursday, 29'th Apr 2021
Here is what you should know about investing in these life changing technologies.
Novartis CEO says could boost CureVac vaccine production, if needed
02:29am, Tuesday, 27'th Apr 2021
Novartis is scaling up facilities to make COVID-19 vaccine doses for German drugmaker CureVac and could boost production beyond levels agreed so far, Chief Executive Vas Narasimhan said on a conferenc
CureVac's Potential Has Wall Street Sending Mixed Signals
01:54pm, Monday, 26'th Apr 2021
The biotech still has a long way to go to prove itself and justify its current stock valuation.
2 Reasons This COVID Vaccine Latecomer Could Gain Major Market Share
06:30am, Wednesday, 21'st Apr 2021
A big market is in big need of more vaccines.
CureVac in Talks With U.S. Over Next-gen Covid Shot: CEO
09:25pm, Sunday, 18'th Apr 2021
Apr.16 -- CureVac CEO Franz-Werner Haas says the company aims to produce 300 million doses of their mRNA-based vaccine in 2021 and is in discussions with the U.S. and other countries about supplying n
CureVac to Release Results of Covid Vaccine Trials
05:49pm, Thursday, 15'th Apr 2021
Apr.15 -- Kempen & Co Equity Analyst of Life Science Ingrid Gafanhao speaks to Bloomberg's Alix Steel about the Curevac Covid-19 vaccine and it's expected release now that variants are being taken int
CureVac says it is on track with COVID-19 vaccine as it posts earnings update
07:56am, Thursday, 15'th Apr 2021
The German company, which went public last August, said its vaccine is in the final stage of clinical development.
Covid vaccine maker CureVac hopes shot will get EU approval in June
05:44am, Thursday, 08'th Apr 2021
The U.K. and EU have pre-ordered up to 455 million doses of CureVac's mRNA vaccine, subject to regulatory approval.
CureVac Taps Celonic For COVID-19 Vaccine Production
09:27am, Tuesday, 30'th Mar 2021
CureVac BV (NASDAQ: CVAC) has partnered with Celonic Group, a Contract Development, and Manufacturing Organization, to produce CureVac's mRNA-based COVID-19 vaccine candidate, CVnCoV. The commerc
CureVac Expands Late-Stage Trials Of COVID-19 Vaccine Candidate
10:14am, Monday, 22'nd Mar 2021
CureVac BV (NASDAQ: CVAC) plans to expand and further specify the protocols of its ongoing late-stage clinical trials with CVnCoV, its COVID-19 vaccine candidate. CVnCoV efficacy is currently bein
